In the Kaplan-Meier analysis, patients with increased TAGLN2 levels had poorer DSS than those with decreased TAGLN2 levels in LGG, READ, KIRC, KICH, UVM, and PAAD (Figure S3C), whereas higher TAGLN2 expression was associated with better DSS in BRCA. Here, TAGLN2 is linked to pancreatic adenocarcinoma.